Trulieve Posts $230M Q3 Revenue, 64% Margin, $89M Adjusted EBITDA
TRLV has more than doubled off its 52-week low of $4.616.
Summary
Trulieve reported Q3 2026 revenue of $230 million with a 64% gross margin and $148 million in gross profit, producing $89 million of adjusted EBITDA (39% of revenue), $1 million of net income to common shareholders and adjusted EPS of 9 cents. Revenue fell 20% year over year, but that comparison is distorted: prior periods consolidated Harvest's mixed medical and adult-use operations, which were deconsolidated on June 3, 2026, and Q3 now reflects only the medical platform. Cash generation held up, with $74 million from operations and $45 million of free cash flow in the quarter, lifting cash to $327 million. The company also said it received final DEA registrations for state-licensed medical marijuana under the Schedule III rescheduling framework, which removes 280E tax exposure and underpins the NYSE uplisting. Management flagged Georgia, where traffic rose seven-fold after the July 1 program expansion, and Texas as the growth drivers. The 8:30 A.M. ET call will be the first chance to press management on the post-Harvest cost base and the pace of the Georgia and Texas ramp.
At the time of this announcement, TRLV was trading at $11.94 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $4.62 to $13.28. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.